ArticleNAM journal2026
Effect of conazoles on steroidogenesis mapped by extended H295R-CALUX® assay and LC-MS/MS profiling.
Article in NAM journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The H295R assay (OECD TG456) is used to screen chemicals for interference with steroidogenesis, measuring testosterone and estradiol levels as endpoints. Focusing on these two hormones, however, may overlook informative changes in other steroid classes, particularly progestogens and glucocorticoids. Here, we extended the effect-based H295R-CALUX® read-out to include progestogens and glucocorticoids using PR- and GR CALUX® assays. First, we evaluated whether PR- and GR-CALUX® could be used as H295R read-outs by determining whether control samples produced adequate hormone levels and whether responses to control compounds forskolin and prochloraz met predefined criteria. Progestogenic and glucocorticoid activity was consistently quantifiable, forskolin induced both modalities above the predefined threshold, and prochloraz inhibited glucocorticoid activity while increasing progestogenic activity, consistent with upstream pathway inhibition. The extended H295R-CALUX® read-out was then applied to analyse a set of conazoles. Each conazole was first pre-screened for ERα/AR/PR/GR agonism or antagonism and for cytotoxicity to avoid interference from direct receptor activation and cytotoxicity in the H295R read-out. In the H295R assay, all conazoles except 1,2,4-triazole, affected at least one hormone modality, with a common pattern of reduced androgenic, estrogenic and glucocorticoid activity and compound-specific increases or decreases in progestogenic activity. Further, targeted LC-MS/MS steroid profiling mirrored the effect-based results obtained with the H295R-CALUX® read-out and supported the hypothesis of CYP17A1-related perturbations for some conazoles. Overall, the addition of progestogen and glucocorticoid read-outs, alongside androgen and estrogens, enhances the resolution of the H295R assay, hence improving its relevance for endocrine safety assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.